

## **Erwinase**

## **Prior Authorization Request**

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

atient s maine.	Date:
Patient's Name:Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: 🗖 Same as R	equesting Provider
Name:	NPI#:
Fax:	Phone:
	eferring Provider Same as Requesting Provider
Fax:	NPI#: Phone:
Approvals may be subjec	et to dosing limits in accordance with FDA-approved labeling,
	to do sing times in decordance with 1211 approved the cing,
gaantad aans	naudia aud/ou ouiday oo bagad nyaatiga ayidaliyag
accepted com	pendia, and/or evidence-based practice guidelines.
•	pendia, and/or evidence-based practice guidelines.
accepted comp Required Demographic Information:	pendia, and/or evidence-based practice guidelines.
•	
Required Demographic Information:  Patient Weight:	kg
Required Demographic Information:  Patient Weight:  Patient Height:	kg cm
Required Demographic Information:  Patient Weight:  Patient Height:  Please indicate the place of service for the	kg cm e requested drug:
Required Demographic Information:  Patient Weight:  Patient Height:  Please indicate the place of service for the  Ambulatory Surgical	kg cm e requested drug: □ Home □ Off Campus Outpatient Hospital
Required Demographic Information:  Patient Weight:  Patient Height:  Please indicate the place of service for the	kg cm e requested drug: □ Home □ Off Campus Outpatient Hospital
Required Demographic Information:  Patient Weight:  Patient Height:  Please indicate the place of service for the  Ambulatory Surgical  On Campus Outpatient Hospital	kg cm e requested drug: □ Home □ Off Campus Outpatient Hospital
Required Demographic Information:  Patient Weight:  Patient Height:  Please indicate the place of service for the  Ambulatory Surgical  On Campus Outpatient Hospital	kgkgcm e requested drug: □ Home □ Off Campus Outpatient Hospital □ Office
Required Demographic Information:  Patient Weight:  Patient Height:  Please indicate the place of service for the  Ambulatory Surgical  On Campus Outpatient Hospital	kgcm e requested drug:  ☐ Home ☐ Off Campus Outpatient Hospital ☐ Office  Units ☐ ml ☐ Gm ☐ mg ☐ ea ☐ Un

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Erwinase SGM 2292-A – 08/2022.

	iteria Questions:  What is the diagnosis?  Acute lymphoblastic leukemia (ALL)  Lymphoblastic lymphoma  Extranodal natural killer/T-cell lymphoma, nasal type  Other
2.	What is the ICD-10 code?
3.	Is this a request for continuation of therapy with the requested drug? $\square$ Yes $\square$ No If No, skip to #5
4.	Has the patient experienced unacceptable toxicity or disease progression while on the current regimen? ☐ Yes ☐ No No further questions
5.	Will the requested medication be used in conjunction with multi-agent chemotherapy? ☐ Yes ☐ No
Complete the following questions if patient's diagnosis is acute lymphoblastic leukemia or lymphoblastic lymphoma.	
6.	Has the patient previously received and developed hypersensitivity to an E. coli-derived asparaginase (e.g., L-asparaginase, pegaspargase)? If Yes, no further questions. $\square$ Yes $\square$ No
7.	Will the requested medication be used as induction therapy? ☐ Yes ☐ No
	ttest that this information is accurate and true, and that documentation supporting this formation is available for review if requested by Priority Partners.
X	

Date (mm/dd/yy)

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Erwinase SGM 2292-A – 08/2022.

**Prescriber or Authorized Signature**